Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03847909 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT03847909 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 35 participants.
The verdict
NCT03847909, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
Interventions
- DRUG Sterile Normal Saline (0.9% NaCl)
- DRUG DCR-PHXC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03847909
The ClinicalTrials.gov registry entry for NCT03847909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sterile Normal Saline (0.9% NaCl) is the first listed.
NCT03847909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03847909 about?
NCT03847909 is a clinical study titled "A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2". The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
What is the current status of trial NCT03847909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2019-10-28. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT03847909?
The interventions under investigation include: Sterile Normal Saline (0.9% NaCl) (DRUG), DCR-PHXC (DRUG).
Who is sponsoring clinical trial NCT03847909?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.